Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original purpose - from treating addiction to potentially impacting…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from In Good Company with Nicolai Tangen
See all episodes →
43%Venki Ramakrishnan: The Science and Hype of Living Longer
41%Eliot Higgins: How Bellingcat Hunts Down the Truth
39%Horizon Robotics CEO: Car Chips, Mind-Off Driving and China's Speed
Similar episodes from other shows
More like In Good Company with Nicolai Tangen →
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Corner Office Conversation with Eli Lilly's Global CEO David Ricks
42%Hora 25 de los negocios | Revolución adelgazante: entrevista al CEO de la farmacéutica Lilly España
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.